This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: pacemaker

Pacing supplement: Current and future perspectives on cardiac pacing

October 2018 Br J Cardiol 2018;25(suppl 3):S4–S7 doi:10.5837/bjc.2018.s12

Pacing supplement: Current and future perspectives on cardiac pacing

Paul Foley

Abstract

Dr Paul Foley Introduction 2018 marks the 60-year anniversary of the first patient to receive an implantable battery-powered pacemaker.1 In fact, the earliest recorded description of pacing was in 1882, and now countless lives have been saved by pacemaker technology. Subsequent important developments include the development of the implantable cardioverter defibrillator (ICD) in 1980 and then, more recently, one of the most effective cardiac treatments, cardiac resynchronisation therapy, which was first described in 1984. Exciting and disruptive developments in pacing technology may, potentially, herald a sea change in practice, while historic

| Full text
Pacing supplement: Techniques in pacemaker and defibrillator lead extraction

October 2018 Br J Cardiol 2018;25(suppl 3):S35–S39 doi:10.5837/bjc.2018.s18

Pacing supplement: Techniques in pacemaker and defibrillator lead extraction

Osman Najam, Hitesh C Patel, Manav Sohal, Mark M Gallagher

Abstract

Definitions Lead extraction is defined as a procedure in which a cardiovascular implantable electronic device (CIED) lead is removed with the assistance of equipment not routinely used during implantation, or after it has been in situ for more than one year. Lead explant is the removal of a lead that has been implanted for less than one year using only standard implantation stylets. Indications The indications for CIED lead extraction from contemporary international guidelines are summarised in table 1. Table 1. Adapted indications for lead extractions and their class of recommendation1 Epidemiology The number of lead extraction procedures be

| Full text
Pacing supplement: Leadless pacing

October 2018 Br J Cardiol 2018;25(suppl 3):S30–S34 doi:10.5837/bjc.2018.s17

Pacing supplement: Leadless pacing

Paul Roberts

Abstract

Dr Paul R Roberts Introduction Since the first implantation of a pacemaker 60 years ago, the medical world has seen an incredible evolution of these devices. The first pacemaker had limited capability. With time, we have seen changes to lead design that have meant that they are smaller, more robust and last longer. The greatest changes have occurred with the electrical aspects of the devices. There are enhanced algorithms in the devices that make them more physiological, and magnetic resonance imaging (MRI) safe devices are now considered the standard of care. This journey has not been without some challenges, and this therapy continues to be

| Full text
In brief

August 2016 Br J Cardiol 2016;23:98–9

In brief

BJCardio Staff

Abstract

A new portable monitoring device (CardioMessenger Smart, Biotronik) has been launched in the USA. Roughly the size of a smartphone, the device keeps pacemaker, implantable cardioverter defibrillator, and insertable cardiac monitor patients connected to their physician remotely. The device automatically transmits daily reports of cardiac activity via worldwide cellular networks to physicians without intervention from the patient. It also provides fully customisable alerts that can be programmed to the physician’s specifications. Studies have found that home monitoring can significantly reduce hospitalisation, stroke and mortality. The manuf

| Full text

March 2014 Br J Cardiol 2014;21:16

In brief

BJCardio Staff

Abstract

New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo

| Full text
In brief

May 2010 Br J Cardiol 2010;17:117

In brief

BJ Cardio Staff

Abstract

New pocket-sized visualisation tool This new pocket-sized visualisation tool provides ultrasound technology at the point-of-care. Similar in size to a mobile phone and weighing less than one pound, it can give high quality colour images enabling physicians to take a quick look inside the body and detect disease earlier. Vscan™ is marketed by GE Healthcare and has received the CE Mark by the European Union. Heart failure report published A comprehensive review of the quality of heart failure care in England Bridging the quality gap: heart failure, has been published by The Health Foundation. It highlights that prevention is key to imp

| Full text

January 2008 Br J Cardiol 2008;15:7-11

New pacemaker may help more syncope patients

BJCardio editorial team

Abstract

In patients in whom the heart rate drops dramatically before the fainting episode, traditional pacemakers are well established as a good form of therapy. But most patients with recurrent syncope do not experience any clear fall in heart rate ahead of a fainting episode. The new Biotronik Cylos 990 pacemaker, may help these patients by detecting early changes in the body’s control systems ahead of a fainting episode and then working to prevent the fainting episode. The pacemaker also contains a chip enabling remote follow-up of the patient at home.  “This way of supporting pacemaker patients in their everyday lives is the future of cardia

| Full text

November 2004 Br J Cardiol 2004;11:492-4

Palpitations and syncope in primary care

Amit KJ Mandal, George G Kassianos

Abstract

No content available

| Full text

May 2004 Br J Cardiol 2004;11:224-8

Bradycardia and tachycardia occurring in older people: investigations and management

Colin Berry, Andrew C Rankin, Adrian JB Brady

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now